Abicipar pegol - Allergan/Molecular Partners AG

Drug Profile

Abicipar pegol - Allergan/Molecular Partners AG

Alternative Names: AGN-150998; Anti-VEGF DARPin®; DARPin® anti-VEGF product for eye disorders - Molecular Partners/Allergan; MP 0112

Latest Information Update: 14 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Molecular Partners AG
  • Developer Allergan; Molecular Partners AG
  • Class Eye disorder therapies; Peptides; Polyethylene glycols; Proteins
  • Mechanism of Action Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Wet age-related macular degeneration
  • Phase II Diabetic macular oedema

Most Recent Events

  • 08 Feb 2018 Allergan plans a phase III trial for Diabetic macular oedema in the second half of 2018
  • 28 Nov 2017 Allergan initiates enrolment in the phase I PINE trial for Wet age-related macular degeneration in Japan (Intravitreal) (NCT03335852)
  • 20 Oct 2017 Allergan completes a phase I trial for Macular degeneration in USA (Intravitreous) (NCT02859766)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top